Wednesday, April 15, 2020 4:24:18 PM
On page 23 Algernon shows a comparison to Chronic Cough within the industry.
They mention the 2 companies Algernon is going head up against.
BELLUS Health and Merck.
In the illustration below, you see Merck bought the chronic cough drug for USD $1.2B
You're also aware of the fact, Algernon's NP-120 Ifenprodil for Chronic Cough outperformed Merck by 110%.
I assure you there can't be too many people that shares your view of $1 per share max.
That gives Algernon a market cap of USD $100M.
IMO, that's just willy nilly math.
Corporate Presentation - Page 23
algernonpharmaceuticals.com/wp-content/uploads/2018/01/Algernon-1st-Quarter-2020.pdf
/////AMG
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
